Replies to post #251835 on Biotech Values

[Mufaso]

Thanks very much! I was not aware of this and thought that there were only two GLP1/GIP compounds in trials (VK2735 and CT388) to challenge Tirzepatide in obesity.

I did look briefly at HRS-7535 and saw the "phase 2" trial referenced was only enrolling 60. Seems a stretch to call it a phase 2 but I think the "rules are different" in China.

[Zardiw]

$LYRA Bounce? Chart from #DDAmanda - #1 Stock Screener :

Find Winners Early:



Z